Evidence map›Paper›PMID 31549243›Full record

ReviewInsights into imaging2019

Brain MR findings in patients treated with particle therapy for skull base tumors.

Gisela Viselner, Lisa Farina, Federica Lucev, Elena Turpini, Luca Lungarotti, Ana Bacila, Alberto Iannalfi, Emma D'Ippolito, Barbara Vischioni, Sara Ronchi and 4 more

Open access · goldAbstract readReview
In one paragraph

Review in Insights into imaging, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 6 papers.

0numbers the graph read from it
0cells of the map it votes in
6citing papers in PubMed
1.4field-weighted citation impact, top 17% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

6 citing papers in PubMed, 13 citations in OpenAlex.

  1. Review
  2. Article
  3. Article
  4. Article
  5. Article
  6. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

14 authors at 4 institutions in 1 country.

Gisela ViselnerDiagnostic Imaging Unit, National Center of Oncological Hadrontherapy (CNAO), 27100, Pavia, Italy.
Lisa FarinaNeuroradiology Department, IRCCS Mondino Foundation, Pavia, Italy.
Federica LucevDiagnostic Radiology Residency School, University of Pavia, Pavia, Italy.
Elena TurpiniDiagnostic Radiology Residency School, University of Pavia, Pavia, Italy.
Luca LungarottiDepartment of Diagnostic and Interventional Radiology and Neuroradiology, Fondazione IRCCS Policlinico San Matteo, Pavia, Italy.
Ana BacilaNeuroradiology Department, IRCCS Mondino Foundation, Pavia, Italy.
Alberto IannalfiRadiotherapy Unit, National Center of Oncological Hadrontherapy (CNAO), Pavia, Italy.
Emma D'IppolitoRadiotherapy Unit, National Center of Oncological Hadrontherapy (CNAO), Pavia, Italy.
Barbara VischioniRadiotherapy Unit, National Center of Oncological Hadrontherapy (CNAO), Pavia, Italy.
Sara RonchiRadiotherapy Unit, National Center of Oncological Hadrontherapy (CNAO), Pavia, Italy.
Enrico MarchioniUnit of Neuro-oncology, IRCCS Mondino Foundation, Pavia, Italy.
Francesca ValvoRadiotherapy Unit, National Center of Oncological Hadrontherapy (CNAO), Pavia, Italy.
Stefano BastianelloNeuroradiology Department, IRCCS Mondino Foundation, Pavia, Italy.
Lorenzo PredaDiagnostic Imaging Unit, National Center of Oncological Hadrontherapy (CNAO), 27100, Pavia, Italy. lorenzo.preda@cnao.it.ORCID http://orcid.org/0000-0002-5479-2766
National Center for Oncological Hadrontherapy · ITUniversity of Pavia · ITFondazione Istituto Neurologico Nazionale Casimiro Mondino · ITPoliclinico San Matteo Fondazione · IT

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Nowadays, hadrontherapy is increasingly used for the treatment of various tumors, in particular of those resistant to conventional radiotherapy. Proton and carbon ions are characterized by physical and biological features that allow a high radiation dose to tumors, minimizing irradiation to adjacent normal tissues. For this reason, radioresistant tumors and tumors located near highly radiosensitive critical organs, such as skull base tumors, represent the best target for this kind of therapy. However, also hadrontherapy can be associated with radiation adverse effects, generally referred as acute, early-delayed and late-delayed. Among late-delayed effects, the most severe form of injury is radiation necrosis. There are various underlying mechanisms involved in the development of radiation necrosis, as well as different clinical presentations requiring specific treatments. In most cases, radiation necrosis presents as a single focal lesion, but it can be multifocal and involve a single or multiple lobes simulating brain metastasis, or it can also involve both cerebral hemispheres. In every case, radiation necrosis results always related to the extension of radiation delivery field. Multiple MRI techniques, including diffusion, perfusion imaging, and spectroscopy, are important tools for the radiologist to formulate the correct diagnosis. The aim of this paper is to illustrate the possible different radiologic patterns of radiation necrosis that can be observed in different MRI techniques in patients treated with hadrontherapy for tumors involving the skull base. The images of exemplary cases of radiation necrosis are also presented.

Indexed as

HadrontherapyMultiparametric magnetic resonance imagingRadiation necrosis brain

Identifiers

PMID31549243
PMCPMC6757093
OpenAlexW2973717433

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.